Helsinn Healthcare SA
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Holding
- Established
- 1976-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.helsinn.com
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 50
- Registration Number
- NCT01912274
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 250
- Registration Number
- NCT01887314
- Locations
- 🇮🇹
Ospedale S. Gerardo, Monza, Italy
🇮🇹Istituto Nazionale dei Tumori, Milan, Italy
🇮🇹IEO -Istituto Europeo di Oncologia-, Milan, Italy
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 102
- Registration Number
- NCT01873703
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Weill Cornell Medical Center, New York, New York, United States
🇺🇸Florida Cancer Specialists North, Saint Petersburg, Florida, United States
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 138
- Registration Number
- NCT01543451
- Locations
- 🇧🇬
Department of Chemotherapy, Complex Oncology Center, Ruse, Bulgaria
🇧🇬Chemotherapy Department, Complex Oncology Center, Shumen, Bulgaria
ðŸ‡ðŸ‡ºPetz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary, Gyor, Hungary
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 502
- Registration Number
- NCT01442376
- Locations
- 🇺🇸
A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Nemours Children's Clinic, Pensacola, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 670
- Registration Number
- NCT01395901
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
🇵🇱Department of Intensive Care and Anesthesiology, Olsztyn, Poland
🇺🇸Shoals Medical Research, LLC, Sheffield, Alabama, United States
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 413
- Registration Number
- NCT01376297
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
🇺🇸East Valley Hematology and Oncology Medical Group, Burbank, California, United States
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 743
- Registration Number
- NCT01363479
- Locations
- 🇺🇸
Facey Medical Group, Mission Hills, California, United States
🇺🇸Northern Utah Associates [Hematology/ Oncology], Ogden, Utah, United States
🇺🇸Genesis Cancer Centre, Hot Springs, Arkansas, United States
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 1455
- Registration Number
- NCT01339260
- Locations
- 🇺🇸
Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States
🇺🇸The John R Marsh Cancer Center, Hagerstown, Maryland, United States
🇺🇸Compassionate Cancer Centre Medical Group, Fountain Valley, California, United States
Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 150
- Registration Number
- NCT00828295
- Locations
- 🇷🇺
Federal State Institution St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the Federal Agency for High-Tech Medical Care, St. Petersburg, Russian Federation
🇷🇺State Healthcare Institution 'Regional Pediatric Clinical Hospital', Yaroslavl, Russian Federation
🇺🇦Cherkassy Regional Hospital, Pediatric Surgery Department, Cherkassy, Ukraine